AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25746695 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilatory time (VT) during first admission
Number of subjects: 42
Study 23340588 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure support
Number of subjects: 316
Study 23340588 — intervention group
Group type: COMPARATOR
Intervention: Tracheostomy collar
Number of subjects: 316
Study 20931221 — intervention group
Group type: EXPERIMENTAL
Intervention: MODs 6A-F
Number of subjects: 9
Study 20931221 — intervention group
Group type: COMPARATOR
Intervention: MODs 1-6A
Number of subjects: 9
Study 20931221 — intervention group
Group type: COMPARATOR
Intervention: MODs 1-6B
Number of subjects: 9
Study 20931221 — intervention group
Group type: EXPERIMENTAL
Intervention: MODs 1-6A, 1-6B, and 6A-F
Number of subjects: 9
Study 19942752 — intervention group
Group type: EXPERIMENTAL
Intervention: ZeroFly plastic sheeting treated with deltamethrin
Number of subjects: 3
Study 19942752 — intervention group
Group type: COMPARATOR
Intervention: Untreated plastic sheet
Number of subjects: 3
Study 19942752 — intervention group
Group type: COMPARATOR
Intervention: No sheet area
Number of subjects: 3
Study 16389539 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GR‐1
Number of subjects: 0
Study 16389539 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri B‐54 and RC‐14
Number of subjects: 0
Study 16389539 — intervention group
Group type: COMPARATOR
Intervention: Probiotics (general)
Number of subjects: 0
Study 15573828 — intervention group
Group type: EXPERIMENTAL
Intervention: Education programme (stroke information manual and education meetings every two weeks)
Number of subjects: 170
Study 15573828 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (control group)
Number of subjects: 170
Study 11391261 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin‐clavulanate potassium (2-week course)
Number of subjects: 203
Study 11391261 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antibiotics)
Number of subjects: 203
Study 11391261 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between groups
Number of subjects: 203
Study 9404747 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ipratropium bromide (IB) and albuterol sulfate (ALB)
Number of subjects: 652
Study 9404747 — intervention group
Group type: COMPARATOR
Intervention: Albuterol sulfate (ALB)
Number of subjects: 652
Study 9404747 — intervention group
Group type: COMPARATOR
Intervention: Ipratropium bromide (IB)
Number of subjects: 652
Study 7952987 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 283
Study 7952987 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 283
Study 7952987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 283
Study 3422105 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (20 mg twice daily)
Number of subjects: 16
Study 3422105 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 30457948 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental varnish containing casein phosphopeptide‐amorphous calcium phosphate and fluoride (CPP‐ACP, MI varnish, GC Europe)
Number of subjects: 12
Study 30457948 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioglass and fluoride (BGA, Experimental, Dentsply Sirona)
Number of subjects: 12
Study 30457948 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride alone (NUPRO, Dentsply Sirona)
Number of subjects: 12
Study 30457948 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control group)
Number of subjects: 12
Study 28517948 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping With Voices (CWV) program
Number of subjects: 37
Study 28517948 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 37
Study 28053714 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Respiratory Muscle Training (RMT)
Number of subjects: 3
Study 28053714 — intervention group
Group type: COMPARATOR
Intervention: Sham Respiratory Muscle Training (RMT)
Number of subjects: 3
Study 24078975 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythritol powder applied by air-polishing (EPAP)
Number of subjects: 40
Study 24078975 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP)
Number of subjects: 40
Study 16371080 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. atilmotin 6, 30, 60 microg
Number of subjects: 0
Study 16371080 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 0
Study 12810502 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of alefacept
Number of subjects: 507
Study 12810502 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg of alefacept
Number of subjects: 507
Study 12810502 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 507
Study 10021470 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone treatment (0.3 mg per kilogram of body weight per week) for 2 to 10 years
Number of subjects: 121
Study 10021470 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone treatment
Number of subjects: 121
Study 8672321 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-10 during CPB
Number of subjects: 20
Study 8672321 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro-inflammatory cytokines (IL-1, IL-8, TNF)
Number of subjects: 20
Study 8672321 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1 receptor antagonist (IL-1ra) and TNF soluble receptors (TNFsr)
Number of subjects: 20
Study 8672321 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte adhesion molecule expression
Number of subjects: 20
Study 8672321 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 175 micrograms with heparin 1050 u
Number of subjects: 20
Study 8672321 — intervention group
Group type: COMPARATOR
Intervention: Heparin alone 1050 u
Number of subjects: 20
Study 1981223 — intervention group
Group type: COMPARATOR
Intervention: Control group (vasodilators with no known inhibitory effect on platelet function)
Number of subjects: 590
Study 1981223 — intervention group
Group type: COMPARATOR
Intervention: Dipyridamole (DP) 50 mg 3 times a day
Number of subjects: 590
Study 1981223 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA 300 mg once a day
Number of subjects: 590
Study 1981223 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA 300 mg once in combination with DP 50 mg 3 times a day
Number of subjects: 590
Study 1981223 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA 100 mg once a day
Number of subjects: 590
Study 1981223 — intervention group
Group type: COMPARATOR
Intervention: Non-ASA group (combined control and DP groups)
Number of subjects: 590
Study 1981223 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA3 group (combined ASA 300 mg and ASADP groups)
Number of subjects: 590
Study 7283711 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 11
Study 7283711 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 29328522 — intervention group
Group type: EXPERIMENTAL
Intervention: Cassava flour slurry (CFS)
Number of subjects: 30
Study 29328522 — intervention group
Group type: COMPARATOR
Intervention: Commercial gel
Number of subjects: 30
Study 27787547 — intervention group
Group type: EXPERIMENTAL
Intervention: Girentuximab (50 mg loading dose followed by 20 mg weekly for 24 weeks)
Number of subjects: 864
Study 27787547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 864
Study 27787547 — intervention group
Group type: EXPERIMENTAL
Intervention: Girentuximab
Number of subjects: 864
Study 25556383 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (1200 mg/day)
Number of subjects: 32
Study 25556383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 24005138 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% liposomal lidocaine
Number of subjects: 10
Study 24005138 — intervention group
Group type: COMPARATOR
Intervention: 2.5% lidocaine and 2.5% prilocaine
Number of subjects: 10
Study 21439642 — intervention group
Group type: EXPERIMENTAL
Intervention: povidone iodine 2.5% solution
Number of subjects: 394
Study 21439642 — intervention group
Group type: COMPARATOR
Intervention: tetracycline 1% ointment
Number of subjects: 394
Study 18201138 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate 0.2% twice-daily
Number of subjects: 26
Study 18201138 — intervention group
Group type: COMPARATOR
Intervention: Artificial tears (control)
Number of subjects: 26
Study 15842288 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocolysis for repeat external cephalic version (ECV)
Number of subjects: 124
Study 12898792 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (Andriol) 160 mg/day for 3 months
Number of subjects: 39
Study 12898792 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 12898792 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (Andriol)
Number of subjects: 39
Study 10534261 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (VGB) at a target dose of 50 mg/kg
Number of subjects: 14
Study 10534261 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 14
Study 8707781 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 50, 100, or 250 micrograms
Number of subjects: 331
Study 1746428 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (2.5 mg orally at baseline and again 12 hours later)
Number of subjects: 89
Study 1746428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 7185276 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehearsal group
Number of subjects: 0
Study 7185276 — intervention group
Group type: EXPERIMENTAL
Intervention: Modeling group
Number of subjects: 0
Study 7185276 — intervention group
Group type: COMPARATOR
Intervention: Discussion control group
Number of subjects: 0
Study 31772615 — intervention group
Group type: EXPERIMENTAL
Intervention: Fimasartan
Number of subjects: 80
Study 31772615 — intervention group
Group type: COMPARATOR
Intervention: Valsartan
Number of subjects: 80
Study 27604240 — intervention group
Group type: EXPERIMENTAL
Intervention: PEP + omega-3
Number of subjects: 72
Study 26151891 — intervention group
Group type: EXPERIMENTAL
Intervention: Microscopic retroperitoneal varicocelectomy (MRV)
Number of subjects: 80
Study 26151891 — intervention group
Group type: COMPARATOR
Intervention: Microscopic subinguinal varicocelectomy (MSV)
Number of subjects: 80
Study 26151891 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MRV and MSV
Number of subjects: 80
Study 25118794 — intervention group
Group type: EXPERIMENTAL
Intervention: Positively Smoke Free on the Web (PSFW)
Number of subjects: 138
Study 25118794 — intervention group
Group type: COMPARATOR
Intervention: Standard care (brief advice to quit and self-help brochure)
Number of subjects: 138
Study 22261824 — intervention group
Group type: EXPERIMENTAL
Intervention: Low amount-high intensity
Number of subjects: 163
Study 22261824 — intervention group
Group type: EXPERIMENTAL
Intervention: High amount-high intensity
Number of subjects: 163
Study 22261824 — intervention group
Group type: EXPERIMENTAL
Intervention: Low amount-moderate intensity
Number of subjects: 163
Study 20020589 — intervention group
Group type: EXPERIMENTAL
Intervention: Compomer restoration
Number of subjects: 20
Study 20020589 — intervention group
Group type: COMPARATOR
Intervention: Amalgam restoration
Number of subjects: 20
Study 17335327 — intervention group
Group type: EXPERIMENTAL
Intervention: Day hospital care
Number of subjects: 1117
Study 17335327 — intervention group
Group type: COMPARATOR
Intervention: Conventional inpatient care
Number of subjects: 1117
Study 15220229 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial therapy for UTI
Number of subjects: 765
Study 15220229 — intervention group
Group type: COMPARATOR
Intervention: Control group (type 2 diabetic patients without UTI)
Number of subjects: 765
Study 11821986 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% aqueous solution of poloxamine 1107 (treated)
Number of subjects: 6
Study 11821986 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 6
Study 9822096 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 15
Study 9822096 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS
Number of subjects: 15
Study 9822096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 8558397 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiseptic mouthrinse
Number of subjects: 20
Study 8558397 — intervention group
Group type: COMPARATOR
Intervention: 5% hydroalcohol placebo mouthrinse
Number of subjects: 20
Study 2758540 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 0.04 mg.kg‐1 with varying doses of atropine (0.014 to 0.04 mg.kg‐1) in Group A
Number of subjects: 70
Study 2758540 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 0.06 mg.kg‐1 with varying doses of atropine (0.02 to 0.04 mg.kg‐1) in Group B
Number of subjects: 70
Study 900826 — intervention group
Group type: EXPERIMENTAL
Intervention: 5000 units of subcutaneous heparin 2 hr before the operation, then 5000 units 3 times daily for 6 days
Number of subjects: 99
Study 900826 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 99
Study 900826 — intervention group
Group type: EXPERIMENTAL
Intervention: 5000 units of subcutaneous heparin
Number of subjects: 99
Study 31557874 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing desks
Number of subjects: 0
Study 31557874 — intervention group
Group type: COMPARATOR
Intervention: Traditional desks
Number of subjects: 0
Study 27072928 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity and fitness programme (3 times a week for 8 months)
Number of subjects: 151
Study 27072928 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 151
Study 26230296 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 51
Study 26230296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 26866095 — intervention group
Group type: EXPERIMENTAL
Intervention: Boric acid (powder every night for a week)
Number of subjects: 150
Study 26866095 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole
Number of subjects: 150
Study 21639658 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief alliance-training workshop
Number of subjects: 57
Study 21639658 — intervention group
Group type: COMPARATOR
Intervention: Delayed-training control condition
Number of subjects: 57
Study 21639658 — intervention group
Group type: EXPERIMENTAL
Intervention: Both conditions
Number of subjects: 57
Study 19622685 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg nefiracetam per day
Number of subjects: 70
Study 19622685 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg nefiracetam per day
Number of subjects: 70
Study 19622685 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 16536342 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etching adhesives (AdheSE, Adper Prompt L-Pop, Clearfil SE Bond, iBond, OptiBond Solo Plus - Self-Etch Adhesive System, Xeno III)
Number of subjects: 48
Study 16536342 — intervention group
Group type: EXPERIMENTAL
Intervention: Etch-and-rinse adhesive system (OptiBond FL)
Number of subjects: 48
Study 16536342 — intervention group
Group type: COMPARATOR
Intervention: Negative control (Gluma Classic with 0.5 M EDTA)
Number of subjects: 48
Study 16536342 — intervention group
Group type: COMPARATOR
Intervention: Positive control (OptiBond FL)
Number of subjects: 48
Study 14641263 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 0.5% eye drops, one drop every 15 min for four doses prior to surgery
Number of subjects: 59
Study 14641263 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin 0.3% eye drops, one drop every 15 min for four doses prior to surgery
Number of subjects: 59
Study 11677363 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 h SBP or PP standard deviation
Number of subjects: 1663
Study 11677363 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 h average SBP or PP
Number of subjects: 1663
Study 11677363 — intervention group
Group type: EXPERIMENTAL
Intervention: Day-night or clinic-day SBP and PP differences
Number of subjects: 1663
Study 9373657 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular artemether
Number of subjects: 175
Study 9373657 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemisinin suppositories
Number of subjects: 175
Study 9373657 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate (intramuscular)
Number of subjects: 175
Study 9373657 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous artesunate
Number of subjects: 175
Study 1554153 — intervention group
Group type: EXPERIMENTAL
Intervention: Deproteinized hemodialysate 20% for infusion, 20 intra-arterial infusions over 4 weeks
Number of subjects: 58
Study 1554153 — intervention group
Group type: COMPARATOR
Intervention: Bencyclan 250 mg in 250 mL saline 0.9%, 20 intra-arterial infusions over 4 weeks
Number of subjects: 58
Study 1554153 — intervention group
Group type: EXPERIMENTAL
Intervention: Deproteinized hemodialysate 20% for infusion
Number of subjects: 58
Study 3993535 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol
Number of subjects: 0
Study 3993535 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3993535 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study 3993535 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine
Number of subjects: 0
Study 30773148 — intervention group
Group type: EXPERIMENTAL
Intervention: Affect-focused treatments (Interpersonal Psychotherapy for PTSD; Panic-Focused Psychodynamic Psychotherapy for PD)
Number of subjects: 59
Study 30773148 — intervention group
Group type: COMPARATOR
Intervention: Exposure-based treatments (Prolonged Exposure for PTSD; Cognitive Behavioral Therapy or Applied Relaxation Training for PD)
Number of subjects: 59
Study 29704456 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% tretinoin cream applied three nights a week
Number of subjects: 24
Study 29704456 — intervention group
Group type: COMPARATOR
Intervention: 5% tretinoin peel applied every 2 weeks
Number of subjects: 24
Study 27930530 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (infused at 0.1 μg/kg/min and demand boluses of 0.1 μg/kg)
Number of subjects: 152
Study 27930530 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 152
Study 27930530 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 152
Study 24484541 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive physiotherapy involving both hospital and home-based functional exercise rehabilitation
Number of subjects: 440
Study 24484541 — intervention group
Group type: COMPARATOR
Intervention: Standard of care consisting of home exercises
Number of subjects: 440
Study 21732113 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) at 830 nm, 86 mW, 92.1 J/cm², 0.25 J, 3 s/point, at 20 points, repeated every 48 hours for 14 days
Number of subjects: 8
Study 21732113 — intervention group
Group type: COMPARATOR
Intervention: Placebo (simulated irradiation)
Number of subjects: 8
Study 20232173 — intervention group
Group type: COMPARATOR
Intervention: T-tube
Number of subjects: 122
Study 20232173 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary closure
Number of subjects: 122
Study 19099235 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual release tablet (DRT-1) 300 mg
Number of subjects: 0
Study 19099235 — intervention group
Group type: COMPARATOR
Intervention: Conventional immediate release tablet (Daxfen, 300 mg)
Number of subjects: 0
Study 15796633 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased therapist directiveness (interpretation, confrontation, introduction of topics)
Number of subjects: 141
Study 15796633 — intervention group
Group type: COMPARATOR
Intervention: Low therapist directiveness
Number of subjects: 141
Study 11961148 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin-resistant group A streptococci isolates
Number of subjects: 100
Study 11961148 — intervention group
Group type: COMPARATOR
Intervention: Community isolates of group A streptococci
Number of subjects: 100
Study 10646165 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol condition (BAC 0.10%)
Number of subjects: 22
Study 10646165 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained wakefulness condition (28 hours awake)
Number of subjects: 22
Study 10646165 — intervention group
Group type: COMPARATOR
Intervention: Placebo condition (non-alcoholic beverage)
Number of subjects: 22
Study 8698253 — intervention group
Group type: EXPERIMENTAL
Intervention: Infected premature infants
Number of subjects: 49
Study 2132274 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewable tablets containing pyridoxine and heat killed lactic bacteria
Number of subjects: 245
Study 2132274 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets with pyridoxine only
Number of subjects: 245
Study 513885 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered health history questionnaire (SAHHQ)
Number of subjects: 77
Study 513885 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 77
Study 6278914 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged small dose propranolol (30 mg daily for 2 weeks)
Number of subjects: 9
Study 6278914 — intervention group
Group type: COMPARATOR
Intervention: Serial dose reduction of propranolol (for 6 to 9 days)
Number of subjects: 9
Study 6278914 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy (for 2 additional weeks after dose reduction)
Number of subjects: 9
Study 6278914 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged small dose propranolol (30 mg daily)
Number of subjects: 9
Study 31359178 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g IA‐TXA
Number of subjects: 80
Study 31359178 — intervention group
Group type: COMPARATOR
Intervention: 500 mg IA‐TXA
Number of subjects: 80
Study 31359178 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study 27893569 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of Compensatory Sit-to-Stand Maneuvers in People With Dementia (ACSID)
Number of subjects: 97
Study 28026727 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic IDSD implantation
Number of subjects: 12